Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

The data from two Phase III trials demonstrated GLP-1/glucagon agonist’s efficacy in reducing blood glucose and weight.

Eli Lilly(NYSE: LLY) might just be the hottest pharmaceutical company on the planet right now. The company is the developer of a number of blockbuster drugs including Verzenio, Trulicity ...

The demand for medications like Ozempic continues to cause shortages for both those seeking weight loss and patients with ...

"It is critical that only sound science makes its way into the courtroom, and Lilly was pleased to share information about Mounjaro and Trulicity during Science Day," said an Eli Lilly ...

For a long time, Eli Lilly and Company (NYSE:LLY) ‘s success has been largely dependent on its best-selling diabetes medication, Trulicity, for expansion. However, with the green light for ...

For years, Eli Lilly's business has relied heavily on top-selling diabetes drug Trulicity for growth. But with the approval of Mounjaro for diabetes and Zepbound for weight loss, it's a much ...